Analysts See $-0.15 EPS for Asterias Biotherapeutics, Inc. (AST)

March 14, 2018 - By Peter Erickson

 Analysts See $ 0.15 EPS for Asterias Biotherapeutics, Inc. (AST)

Analysts expect Asterias Biotherapeutics, Inc. (NYSEAMERICAN:AST) to report $-0.15 EPS on March, 27.They anticipate $0.03 EPS change or 16.67 % from last quarter’s $-0.18 EPS. After having $-0.15 EPS previously, Asterias Biotherapeutics, Inc.’s analysts see 0.00 % EPS growth. The stock increased 2.56% or $0.05 during the last trading session, reaching $2. About 98,157 shares traded. Asterias Biotherapeutics, Inc. (NYSEAMERICAN:AST) has risen 4.43% since March 14, 2017 and is uptrending. It has underperformed by 12.27% the S&P500.

Asterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapies in the fields of cell therapy and regenerative medicine. The company has market cap of $108.30 million. The firm develops therapeutic products in the areas of neurology and oncology. It currently has negative earnings. The Company’s clinical stage programs include AST-OPC1, a therapy derived from pluripotent stem cells that has completed a Phase I clinical trial for the treatment of thoracic spinal cord injuries; and that is in Phase I/IIa clinical trial for treating cervical spinal cord injuries, as well as for the treatment of multiple sclerosis and white matter stroke.

More news for Asterias Biotherapeutics, Inc. (NYSEAMERICAN:AST) were recently published by:, which released: “Asterias Biotherapeutics (AST) Reports Update on AST-OPC1 Phase 1/2a Clinical …” on February 28, 2018.‘s article titled: “Asterias Biotherapeutics to Report Fourth Quarter and Full Year 2017 Results …” and published on March 09, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: